Indian J Otolaryngol Head Neck Surg:医生对过敏性鼻炎和治疗的看法

2019-12-13 AlexYang MedSci原创

尽管过敏性鼻炎(AR)具有较高的患病率且对生活质量影响较大,但是该疾病仍旧是治疗不足。更多的是,AR与上呼吸道感染(URTI)之间的关系很少有探索。最近,有研究人员评估了医生对AR和RUTI的认识以及治疗实践情况。研究基于调查问卷,共电话访问了300名医生,其中会诊医师(CP): 33%,普通医师(GP): 32%,ENT外科医生:16%,儿科医生:11%,过敏症专家:8%。1个月中,CPs(33

尽管过敏性鼻炎(AR)具有较高的患病率且对生活质量影响较大,但是该疾病仍旧是治疗不足。更多的是,AR与上呼吸道感染(URTI)之间的关系很少有探索。

最近,有研究人员评估了医生对AR和RUTI的认识以及治疗实践情况。研究基于调查问卷,共电话访问了300名医生,其中会诊医师(CP): 33%,普通医师(GP): 32%,ENT外科医生:16%,儿科医生:11%,过敏症专家:8%。1个月中,CPs(33%)和GPs(32%)与其他专家相比治疗更多的AR患者。根据医生的观点,大约29.6%的AR患者在1个月内发展为URTI。大多数医生(98%)认为当前的URTI可以作为未诊断AR的预示因子,同时也认为AR可以作为URTI风险增加的诱发因子。大约62%的医生同意AR的早期诊治和治疗能够减少并发症的产生,如URTI。大多数倾向使用的一线和二线(单独使用或者组合使用)AR治疗药物为口服抗组胺药(41%)和鼻内皮质类固醇(40%)。不考虑医生的专业领域和经验,他们的治疗方法是相似的。

最后,研究人员指出,他们的调查表明了明确的AR诊断和治疗诊断是需要的。

原始出处:

Prabhat D, Sholapuri D, Uchit G. Physicians' Perception on Allergic Rhinitis and Its Management: A Questionnaire Based Survey. Indian J Otolaryngol Head Neck Surg. Nov 2019

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047195, encodeId=ef59204e19504, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jan 30 06:39:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639279, encodeId=794a16392e99a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 11 22:39:00 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044116, encodeId=df53204411663, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 26 06:39:00 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469145, encodeId=daf01469145c6, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Sun Dec 15 04:39:00 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047195, encodeId=ef59204e19504, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jan 30 06:39:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639279, encodeId=794a16392e99a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 11 22:39:00 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044116, encodeId=df53204411663, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 26 06:39:00 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469145, encodeId=daf01469145c6, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Sun Dec 15 04:39:00 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047195, encodeId=ef59204e19504, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jan 30 06:39:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639279, encodeId=794a16392e99a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 11 22:39:00 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044116, encodeId=df53204411663, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 26 06:39:00 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469145, encodeId=daf01469145c6, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Sun Dec 15 04:39:00 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047195, encodeId=ef59204e19504, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Jan 30 06:39:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639279, encodeId=794a16392e99a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 11 22:39:00 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044116, encodeId=df53204411663, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 26 06:39:00 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469145, encodeId=daf01469145c6, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Sun Dec 15 04:39:00 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
    2019-12-15 xiaogang319

相关威廉亚洲官网

Eur Respir J:生命早期暴露于空气污染与儿童哮喘、过敏性鼻炎和湿疹的发生率

由此可见,暴露于氧化性空气污染物(O3和NO2)而不是PM2.5与儿童患哮喘和湿疹的风险增加相关。这表明改善空气质量可能有助于预防儿童期和青春期的哮喘和其他过敏性疾病。

J Diet Suppl:饮食中补充鹌鹑蛋对过敏性鼻炎影响效果研究

之前的数据表明基于鹌鹑蛋的专利混合物对过敏原挑战诱导的过敏性鼻炎(AR)症状具有潜在的治疗作用。因此,有研究人员调查了相似的饮食补充对AR患者治疗的安全性和效果情况,其中包括了鹌鹑蛋的生物活性成分及锌矿物质。研究包括了77名成年患者,年龄在18-60岁,且具有轻度和间歇性的AR。研究是一个单臂和开放标签的试验。患者的响应通过2次的峰值鼻吸气流量(PNIF)测量(第1天/visit1和第7天/vis

Int J Biometeorol:PM2.5与过敏性鼻炎日门诊量相关性研究

关于颗粒性物质PM2.5与过敏性鼻炎(AR)患者就诊数之间的相关性证据有限,尤其是在空气污染极度严重的国家中。最近,有研究人员阐释了中国北京居民中,PM2.5与AR日门诊量之间的相关性。研究总共包括了229685次AR就诊。在2010年1月1日到2012年6月30日之间每天的PM2.5浓度均值为99.5 (75.3) μg/m3。研究人员发现,PM2.5每增加10μg/m3,AR患者的就诊数量就会

BMC Pediatr:儿科中特异性疾病与贫血相关性研究

特应性疾病,比如过敏性皮肤炎、过敏性鼻炎和哮喘均是儿科患者中常见的炎症疾病。最近,有研究人员调查了儿科患者中是否这些特应性炎症疾病与贫血相关。研究是一个代表性的研究,数据来源于2016年韩国HIRA儿科数据库资料。研究总共包括了846718名儿科患者。其中,19594名(2.31%)诊断为缺铁性贫血(IDA)。包含协变量的逻辑回归分析阐释了特应性疾病与IDA之间存在相关性。其中,过敏性皮肤炎中ID

Int Arch Allergy Immunol:过敏性鼻炎患者中舌下和皮下免疫治疗CD4+CD25+FoxP3调控T细胞和血清细胞因子变化研究

很少有研究直接比较皮下免疫治疗(SCIT)和舌下免疫治疗(SLIT)在免疫应答方面的情况。最近,有研究人员直接比较了SLIT和SCIT在对屋尘螨过敏的过敏性鼻炎患者中的临床效果和免疫响应情况。研究包括了67名中度到重度AR患者,他们患有或者不患有哮喘,年龄在5-55岁,并以2:2:1的比例随机分配到SLIT治疗组(n=27)、SCIT组(n=26)和安慰剂组(n=14)。研究发现,在1年的治疗后,

Allergol Immunopathol (Madr):过敏性鼻炎患者中皮刺测试与血清特异性免疫球蛋白E相关性研究

美洲蟑螂是一种常见的过敏性鼻炎(AR)患者的气源性过敏原。皮刺测试(SPT)与美洲蟑螂特异性免疫球蛋白(slgE)之间的关系仍旧不确定。最近,有研究人员评估了SPT与美洲蟑螂slgE在AR患者中的相关性情况。研究是一个代表性的研究,AR患者的年龄在6-25岁,进行的时间为2013年9月到2014年10月。研究共包括了67名AR患者,平均年龄为15岁。研究发现,SPT和美洲蟑螂slgE分别在患者中的